We all have heard the exciting news about Pfizer’s COVID-19 vaccine: a possible savior and source of hope for years to come. According to a LiveScience article by Nicoletta Lanese, “an antibody cocktail designed to prevent and treat COVID-19” entered late-stage trials over the summer. Scientists have been working to find an effective treatment that doesn’t have as many limitations as current findings. A treatment known as convalescent plasma therapy has been circulating clinical trials. It is not FDA-approved and therefore not available to the public. Antibodies are extracted from recovered COVID-19 patients and injected into sick patients in order to boost their immune systems. This method is too unreliable and unpredictable. The plasma donors all have a variety of antibodies. Some have proven to be effective against the virus by not letting it enter cells in the first place. On the other hand, nothing is guaranteed and a patient could be injected with antibodies that have no effect against the virus. To reduce this risk, drug developers have noted the effective antibodies against SARS-CoV-2 and mass produced them in a lab.
Another possible therapy called REGN-COV2 has also entered a late phase in its clinical trial. It supposedly has two antibodies that can prevent the virus from infecting healthy cells by binding to the spike protein. Hopefully the FDA approves the drug at the end of its current phase (phase 3), so short and long-term effects can be monitored. The Co-Founder, President, and Chief Scientific Officer of Regeneron, Dr. George Yancopoulos, released this statement: “We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic.” Many other pharmaceutical companies continue with their trials to search for antibody treatments against the SARS-CoV-2 virus. The universal goal is to find a longer-term solution and stop the rising mortality count.
I originally chose the topic of prevention, because I thought it was only going to include mask-wearing and social distancing. It’s incredibly interesting that this article is another scientific take on preventative measures. The article shows how hard scientists and companies are working on developing a treatment. My main intention for this topic was to show how important it is for everyone to partake in the effort to stunt the spread of the pandemic. With recommended safety procedures as well as current trials, I’m optimistic that there will be great progress in our near future. I was able to link this to our AP Biology class, because we recently covered the immune system! The article refers to antibodies, and I know that they are the humoral defenses that go for pathogens. These antibodies are originally secreted from B-Plasma cells in order to bind to and neutralize the pathogens. By using plasma from recovered patients, I assume they are relying on the B-Memory cells to prevent infection/re-infection in other patients.
Please let me know what your thoughts are in the comments! How much longer do you think we’ll have to wait? Do these new updates give you hope about returning to a state of normalcy? I’d love to know.
Since the summer of 2020 (when this article was released), a lot has changed. Regeneron’s antibody cocktail was granted an Emergency Use Authorization in November. While this seemed to be heading the trials towards an optimistic future, that was not the case. Presently, only the Moderna and Pfizer mRNA vaccines are FDA-approved for public use. What happened to REGN-COV2? According to this Washington Post article, 80% of the allocated dosage supply is remaining unused in overcrowded hospitals. There is a common sentiment that resources should not be going towards an “unproven treatment”. The only FDA-approved antibody in the Regeneron cocktail is bamlanivimab. Although we are all eager to return to normalcy, we must be conscious of what is the best for our health.